[Medical treatment of Crohn's disease].
Hiwatashi
N
N
3rd Department of Internal Medicine, Tohoku University School of Medicine.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D015704:CD4 Antigens / Q000276:immunology; D003424:Crohn Disease / Q000628:therapy*; D004750:Enteral Nutrition; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016753:Interleukin-10 / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D008795:Metronidazole; D019804:Mesalamine; D006493:Heparin; D011239:Prednisolone; D001379:Azathioprine